PACIFIC-Stroke: Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following Acute Non-Cardioembolic Ischemic Stroke

 No clue but I guess you can look in here for a reference to BAY 2433334.

Factor XI as a Target for New Anticoagulants

The latest here:

PACIFIC-Stroke: Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following Acute Non-Cardioembolic Ischemic Stroke 

PACIFIC-Stroke is a randomized, placebo controlled, double-blind, parallel group, dose-finding Phase 2 study to evaluate efficacy and safety of BAY 2433334 in patients following an acute non-cardioembolic ischemic stroke.

Primary outcome measures:

• Number of participants with symptomatic ischemic stroke or covert brain infarcts detected by Magnetic resonance imaging (MRI). Baseline up to 6 months.
• Time from randomization to first occurrence of International Society on Thrombosis and Hemostasis (ISTH) major bleeding and clinically relevant non-major (CRNM) bleeding . Baseline up to 12 months.